The monoclonal anti NCA90 (nonspecific crossreacting antigen-90) antibody was labeled with technetium-99m, which was used for infection, inflammation imaging and tumor markers. The studies on the quality control and preclinical evaluations of this radiopharmaceutical were presented in this report. The radiochemical purity of radioimmunoconjugation was checked by using thin layer chromatography technique. The labeled NCA90 monoclonal antibody was injected into rabbits with the range of radioactive 0.25 mCi, 0.5 mCi, 2.0 mCi and 5.0 mCi doses and the biodistribution, the clearance and the radioimmunoscintigraphy using Gamma Camera Symbia T6 (SPECT-CT) were investigated. The experimented animals were assessed for physical examination and changes in complete blood cells. The whole body imaging of normal and inflammatory rabbits was showed the specific processes of accumulation of granulocytes binding 99mTc-NCA90 antibody in the inflammatory site. The results in the specific binding evaluation of labeled antibody with CD66c antigen and granulocytes in infection patients are more than 70 percent. The results of these experiments show that this radiopharmaceutical is complying with the requirements for radiopharmaceuticals for diagnostic imaging in clinic.